Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Yongxian Hu, MD, Yali Zhou, Mingming Zhang, MD, Wengang Ge, Yi Li, MD, Li Yang, MD, Guoqing Wei, MD, Lu Han, Hao Wang, Xingwang Zhang, PhD, Jiangtao Ren, PhD, He Huang, MD PhD

Blood (2020) 136 (Supplement 1): 52.

https://doi.org/10.1182/blood-2020-142262

Published: 2020

Journal Articles

CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study

Yongxian Hu, MD, Yanlei Zhang, Houli Zhao, MD, Yiyun Wang, Arnon Nagler, MD, Alex Hong Chang, He Huang, MD PhD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-143239

Published: 2020

Journal Articles

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy

Ruimin Hong, Houli Zhao, MD, Yiyun Wang, Yu Chen, Hongliu Cai, Yongxian Hu, MD, Guoqing Wei, MD, He Huang, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139007

Published: 2020

Journal Articles

Cytokine Release Syndrome Is an Independent Risk Factor Associated with Platelet Transfusion Refractoriness after CAR-T Treatment for Relapsed/Refractory Acute Lymphoblast Leukemia

Yadan Liu, graduate student, Yongxian Hu, MD, He Huang

Blood (2019) 134 (Supplement_1): 2448.

https://doi.org/10.1182/blood-2019-129678

Published: 2019

Journal Articles

Maintenance Sorafenib Is Superior to Prophylactic DLI in Improving the Prognosis of FLT3-ITD-Positive AML after Allogeneic HSCT

Jimin Shi, MD, Liqin Cao, MD, Yi Luo, MD, Yanmin Zhao, MD, Yamin Tan, MD, Jian Yu, MD, Xiaoyu Lai, MD, Yuanyuan Zhu, MD, Yongxian Hu, MD, Jingsong He, MD, Jie Sun, MD, Weiyan Zheng, MD, Guoqing Wei, MD, He Huang

Blood (2019) 134 (Supplement_1): 2668.

https://doi.org/10.1182/blood-2019-127594

Published: 2019

Journal Articles

Pre-Transplant MRD Negativity Predicts Favorable Outcomes of CAR-T Therapy Followed By Haploidentical HSCT for Relapsed/Refractory Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study

Yongxian Hu, MD, Zhao Houli, Wei Guoqing, Yi Luo, MD, Ji Min Shi, Jing Chen, Zhang Qing, Song Xianmin, Lei Xiao, PhD, Alex Hong Chang, Didier Blaise, MD PhD, Mohamad Mohty, MD PhD, He Huang

Blood (2019) 134 (Supplement_1): 3213.

https://doi.org/10.1182/blood-2019-128399

Published: 2019

Journal Articles

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies

Feng Zhu, Yongxian Hu, MD, Wei Guoqing, He Huang, Wenjun Wu, MD

Blood (2019) 134 (Supplement_1): 3220.

https://doi.org/10.1182/blood-2019-129649

Published: 2019

Journal Articles

Comparison between Hypercvad and CALLG2008 Protocol in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia:a Single Center Study

Yang Yingying, He Huang, Yongxian Hu, MD

Blood (2019) 134 (Supplement_1): 5122.

https://doi.org/10.1182/blood-2019-129759

Published: 2019

Journal Articles

Galectin-9 from Bone Marrow Mesenchymal Stromal Cells Mediates Immunosuppression on Chimeric Antigen Receptor T Cells

Xinyi Teng, BS, Hao Zhang, MD, Zuyu Liang, MD, Mi Shao, MD, Xiujian Wang, MD, Lijuan Ding, MD, Jiazhen Cui, msc, Yongxian Hu, MD, He Huang, MD PhD

Blood (2019) 134 (Supplement_1): 5609.

https://doi.org/10.1182/blood-2019-131680

Published: 2019

Journal Articles

Potent Anti-Tumor Activity of Bcma CAR-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry

Yongxian Hu, MD, Zhang Yanlei, Guoqing Wei, Chang alex Hong, He Huang

Blood (2019) 134 (Supplement_1): 1859.

https://doi.org/10.1182/blood-2019-130341

Published: 2019

Journal Articles

Therapeutic Effect of Platelet Transfusion in Patients with Acute Lymphocytes Treated with CART Therapy

Liu Yan, MD, Xie Jue, MD PhD, Yongxian Hu, MD PhD, He Huang, MD PhD

Blood (2018) 132 (Supplement 1): 5073.

https://doi.org/10.1182/blood-2018-99-120108

Published: 2018

Journal Articles

Profile of Capillary-Leak Syndrome in Patients Received Chimeric Antigen Receptor T Cell Therapy

Yongxian Hu, MD PhD, Jingjing Feng, MD, Mi Shao, He Huang, MD PhD

Blood (2018) 132 (Supplement 1): 5204.

https://doi.org/10.1182/blood-2018-99-117602

Published: 2018

Journal Articles

Quantification of Non-Hodgkin Lymphoma Disease Burden Using FDG PET-CT Helps Predict the Severity of Cytokine Release Syndrome

Jiasheng Wang, MD, Yongxian Hu, MD PhD, Yanlei Zhang, Guoqing Wei, MD, Huijun Xu, Wenjun Wu, MD, Shaohui Liu, Kangyan Wang, Zhenxing Guo, Alex Hongsheng Chang, Kui Zhao, He Huang, MD PhD

Blood (2018) 132 (Supplement 1): 2997.

https://doi.org/10.1182/blood-2018-99-117983

Published: 2018

Journal Articles

Chimeric Antigen Receptor T-Cell Therapy Shapes T Cell Repertoire in Chinese Patients with B-Cell Acute Lymphocyte Leukemia

Blood (2018) 132 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2018-99-115780

Published: 2018

Journal Articles

Changes of T Lymphocyte Subsets after CAR-T Cell Therapy and Its Clinical Significance

Lijuan Ding, Jiazhen Cui, Yongxian Hu, MD PhD, Huijun Xu, Yanlei Zhang, Shaohui Liu, Kangyan Wang, Zhenxing Guo, AlexH Chang, MD, PhD, He Huang, MD PhD

Blood (2018) 132 (Supplement 1): 1423.

https://doi.org/10.1182/blood-2018-99-117885

Published: 2018

Journal Articles

Comparison of Chimeric Antigen Receptor T Cells from Allogenic or Autologous Sources in Patients with Acute Lymphoblastic Leukemia

Yongxian Hu, MD PhD, Jiasheng Wang, MD, Yanlei Zhang, Guoqing Wei, MD, Huijun Xu, Wenjun Wu, MD, Jian Yu, MD, Yi Luo, MD, Jimin Shi, MD, Shaohui Liu, Kangyan Wang, Zhenxing Guo, Alex HONGSHENG Chang, He Huang, MD PhD

Blood (2018) 132 (Supplement 1): 2691.

https://doi.org/10.1182/blood-2018-99-117910

Published: 2018

Journal Articles

First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia

Yi Luo, Lung-Ji Chang, PhD, Yongxian Hu, MD, Lujia Dong, Guoqing Wei, He Huang, MD PhD

Blood (2015) 126 (23): 3778.

https://doi.org/10.1182/blood.V126.23.3778.3778

Published: 2015

NARROW

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy

Cytokine Release Syndrome Is an Independent Risk Factor Associated with Platelet Transfusion Refractoriness after CAR-T Treatment for Relapsed/Refractory Acute Lymphoblast Leukemia

Maintenance Sorafenib Is Superior to Prophylactic DLI in Improving the Prognosis of FLT3-ITD-Positive AML after Allogeneic HSCT

Pre-Transplant MRD Negativity Predicts Favorable Outcomes of CAR-T Therapy Followed By Haploidentical HSCT for Relapsed/Refractory Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies

Comparison between Hypercvad and CALLG2008 Protocol in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia:a Single Center Study

Galectin-9 from Bone Marrow Mesenchymal Stromal Cells Mediates Immunosuppression on Chimeric Antigen Receptor T Cells

Potent Anti-Tumor Activity of Bcma CAR-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry

Therapeutic Effect of Platelet Transfusion in Patients with Acute Lymphocytes Treated with CART Therapy

Profile of Capillary-Leak Syndrome in Patients Received Chimeric Antigen Receptor T Cell Therapy

Quantification of Non-Hodgkin Lymphoma Disease Burden Using FDG PET-CT Helps Predict the Severity of Cytokine Release Syndrome

Chimeric Antigen Receptor T-Cell Therapy Shapes T Cell Repertoire in Chinese Patients with B-Cell Acute Lymphocyte Leukemia

Changes of T Lymphocyte Subsets after CAR-T Cell Therapy and Its Clinical Significance

Comparison of Chimeric Antigen Receptor T Cells from Allogenic or Autologous Sources in Patients with Acute Lymphoblastic Leukemia

First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only